Sichuan Goldstone Asia Pharmaceutical Inc. Share Price

Equities

300434

CNE100001YX5

Pharmaceuticals

End-of-day quote Shenzhen S.E. 03:30:00 26/04/2024 am IST 5-day change 1st Jan Change
8.59 CNY 0.00% Intraday chart for Sichuan Goldstone Asia Pharmaceutical Inc. +6.44% -22.33%

Financials

Sales 2022 1.24B 171M 14.3B Sales 2023 1.21B 167M 13.91B Capitalization 4.44B 613M 51.13B
Net income 2022 219M 30.22M 2.52B Net income 2023 126M 17.39M 1.45B EV / Sales 2022 4 x
Net cash position 2022 494M 68.15M 5.68B Net cash position 2023 473M 65.34M 5.45B EV / Sales 2023 3.28 x
P/E ratio 2022
25.2 x
P/E ratio 2023
35.7 x
Employees 1,878
Yield 2022 *
-
Yield 2023
-
Free-Float 38.99%
More Fundamentals * Assessed data
Dynamic Chart
Sichuan Goldstone Asia Pharmaceutical Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Hangzhou Solipharma Technology Development Co., Ltd. announced that it expects to receive CNY 69.4857 million in funding from Sichuan Goldstone Asia Pharmaceutical Inc., Hangzhou Huolongguo Investment Management Co., Ltd. and another investor CI
Sichuan Goldstone Asia Pharmaceutical Inc. Approves Management Appointments CI
Sichuan Goldstone Asia Pharmaceutical Inc. Reports Earnings Results for the Nine Months Ended September 30, 2023 CI
Sichuan Goldstone Asia Pharmaceutical Inc.(XSEC:300434) added to S&P Global BMI Index CI
Sichuan Goldstone Asia Pharmaceutical Inc. Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Sichuan Goldstone Asia Pharmaceutical Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Sichuan Goldstone Asia Pharmaceutical Inc. Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Sichuan Goldstone Asia Pharmaceutical Inc. Reports Earnings Results for the Nine Months Ended September 30, 2022 CI
Sichuan Goldstone Asia Pharmaceutical Inc. Reports Earnings Results for the Half Year Ended June 30, 2022 CI
Sichuan Goldstone Asia Pharmaceutical Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022 CI
Sichuan Goldstone Asia Pharmaceutical Inc. Reports Earnings Results for the Nine Months Ended September 30, 2021 CI
Gao Yaping completed the acquisition of 5.1% shares of Sichuan Goldstone Asia Pharmaceutical Inc. from Kuai Yixi and Yang Xiaodong. CI
Sichuan Goldstone Asia Pharmaceutical Inc. Reports Earnings Results for the Half Year Ended June 30, 2021 CI
Gao Yaping signed an equity transfer agreement to acquire 5.1% shares of Sichuan Goldstone Asia Pharmaceutical Inc. from Kuai Yixi and Yang Xiaodong for approximately CNY 170 million. CI
More news
1 week+6.44%
Current month-2.83%
1 month-1.15%
3 months-12.44%
6 months-27.51%
Current year-22.33%
More quotes
1 week
7.98
Extreme 7.98
8.67
1 month
7.79
Extreme 7.79
9.33
Current year
6.89
Extreme 6.89
11.29
1 year
6.89
Extreme 6.89
18.18
3 years
6.89
Extreme 6.89
23.16
5 years
6.70
Extreme 6.7
23.16
10 years
3.88
Extreme 3.875
45.55
More quotes
Managers TitleAgeSince
Chief Executive Officer 56 09/19/09
Director of Finance/CFO 49 25/22/25
Director/Board Member 56 13/17/13
Members of the board TitleAgeSince
Director/Board Member 94 13/17/13
Chief Executive Officer 56 09/19/09
Director/Board Member 66 01/04/01
More insiders
Date Price Change Volume
26/24/26 8.59 0.00% 4,838,500
25/24/25 8.59 +2.26% 3,275,300
24/24/24 8.4 +0.72% 2,189,700
23/24/23 8.34 +2.08% 3,036,100
22/24/22 8.17 +1.24% 2,343,100

End-of-day quote Shenzhen S.E., April 26, 2024

More quotes
Sichuan Goldstone Asia Pharmaceutical Inc., formerly Sichuan Goldstone Orient New Material Equipment Inc, is a China-based company principally engaged in the production and sales of pharmaceutical products, as well as drug agency business. Its main products include health products, cracks and small cracks. The Company is also engaged in the machinery manufacturing business, as well as property leasing and management business. Its machinery products mainly include steel reinforced plastic pipe production line, bead winding steel reinforced pipe production line, production line equipment parts and other equipment. The Company mainly operates its businesses in domestic market.
Calendar
More about the company

Annual profits - Rate of surprise

  1. Stock Market
  2. Equities
  3. 300434 Stock